Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (22361)	6/17/1998 12:35:00 AM
From: Henry Niman	Respond to of 32384

As I recall, the IL-2 (and PHOTOFRIN) projections by Robertson Stephens were very small. The $400 million was solely from retinoid/rexinoid sales and there were no projections for GLYC products. The retinod/rexinoid sales were primarily for cancer. The diabetes contribution was small (and began rather late in the 10 year table) and other metabolic diseases were not included. Later income came primarily from SERM and progesterone related products. STATs came very late in the 10 year table. I thought that the numbers were conservative (and the EPS for 2006 was projected to be $14.55). For details see the Analyst Table at home.att.net Ligand has made a great deal of progress in several areas with 8 products in the clinic and 7 more INDs planned. I believe that they are ahead of schedule in almost all areas. Profitability ($0.10) was projected for 2000. Now 3 analysts (Bear Stearns, Hambrecht & Quist, and Legg Mason) with current projections for 1999 show profits ranging from $0.09 to $0.11.

To: scaram(o)uche who wrote (22361)	6/17/1998 12:36:00 AM
From: Henry Niman	Respond to of 32384

Vector doesn't cover LGND now, but they were big on AMLN right up to and after the first crash: Message 2000176

To: scaram(o)uche who wrote (22361)	6/17/1998 8:39:00 AM
From: Proton	Read Replies (1) \| Respond to of 32384

Re: What a Battlefield This Has Become First off, thank you for your contributions. You have been "accretive" to the sum of knowledge here. You have also provided substantive reasons for being skeptical of LGND, something that Tony has utterly failed to do. However... I don't have that report in my files, but here's one from Peter Ginsberg, Vector Securities, 5/30/95...... projected sales, 1998...... Come on, Richard, now who's being irrelevant? Using Vector to indict RS?? If you didn't have the RS report, you ought to have just let it be. Furthermore... projected sales, 1998...... LGD 1057, $44.6 million, LGD 1069, $26.3 million, IL-2, $4.6 million, and Photofrin, $7.7 million. Well, to give you your due, this does underscore the folly of making sales projections for development stage biotechs, but the IL-2 projections were a big 3.82% of the total. Well, la-teee-da. If you don't have the RS report "in your files," just do the math. :-) BTW, my Henry and Tony needling credentials are well established on this thread. Neither of them is a credible resource for evaluating this stock as an investment, although each comes through in his own way on occasion. Lookng forward to your continuing input. Pý